Loading...
XCSE
COLOb
Market cap14bUSD
Jul 22, Last price  
411.80DKK
1D
-0.56%
1Q
-2.02%
Jan 2017
-13.54%
Name

Coloplast A/S

Chart & performance

D1W1MN
XCSE:COLOb chart
P/E
25.52
P/S
3.33
EPS
16.14
Div yield, %
5.59%
Shrs. gr., 5y
1.11%
Rev. gr., 5y
8.49%
Revenues
27.87b
+3.12%
6,709,000,0008,042,000,0008,463,000,0008,820,000,0009,537,000,00010,172,000,00011,023,000,00011,635,000,00012,428,000,00013,909,000,00014,681,000,00015,528,000,00016,449,000,00017,939,000,00018,544,000,00019,426,000,00022,579,000,00024,500,000,00027,030,000,00027,874,000,000
Net income
3.64b
-28.03%
466,000,000370,000,000715,000,000883,000,0001,243,000,0001,819,000,0002,194,000,0002,711,000,0002,390,000,000899,000,0003,143,000,0003,797,000,0003,845,000,0003,873,000,0004,197,000,0004,825,000,0004,706,000,0004,783,000,0005,052,000,0003,636,000,000
CFO
6.65b
+140.24%
966,000,0001,004,000,0001,324,000,0001,830,000,0001,769,000,0002,205,000,0002,649,000,0003,136,000,0003,149,000,0003,337,000,0003,028,000,0003,251,000,0004,361,000,0004,357,000,0004,759,000,0005,290,000,0005,099,000,0004,226,000,0002,766,000,0006,645,000,000
Dividend
May 18, 20265 DKK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
IPO date
Jan 01, 1983
Employees
14,700
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT